Actinium Pharmaceuticals Selects Medpace Inc. as Clinical Research Organization for Pivotal Phase 3 Iomab-B Trial

Actinium Pharmaceuticals, Inc. (NYSEMKT:ATNM) announced that it has selected Medpace as its Clinical Research Organization (CRO) for its pivotal Phase 3 Iomab-B clinical trial. Medpace is a full service CRO that provides Phase 1 – 4 core development services for drug, biologic and device programs.
Dr. Felix Garzon, M.D., Ph.D., Senior Vice President, Head of Clinical Development for Actinium Pharmaceuticals said:

We worked extremely diligently to identify the right specialist CRO partner for the pivotal Phase 3 Iomab-B clinical trial and we are delighted to announce that we have selected Medpace. Medpace is full service CRO with a global reach, demonstrated track record of successfully managing clinical trials and medical and clinical expertise in the field of bone marrow transplantation. With this major milestone now complete and with Medpace as our partner, we are excited to move into the next chapter of Iomab-B’s clinical development of bringing clinical sites online and enrolling patients.

Click here to view the full press release.